Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
Abstract Background On June 30, 2020, the WHO reported over 10 millions of COVID-19 cases worldwide with over half a million deaths. In severe cases the disease progresses into an Acute Respiratory Distress Syndrome (ARDS), which in turn depends on an overproduction of cytokines (IL-6, TNFα, IL-12,...
Main Authors: | Claudio Ortolani, Elide A. Pastorello |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Clinical and Molecular Allergy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12948-020-00132-7 |
Similar Items
-
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
by: Katya Uzunova, et al.
Published: (2020-11-01) -
How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
by: Regina B. Podlasin, et al.
Published: (2020-08-01) -
The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review
by: Subham Das, et al.
Published: (2021-06-01) -
Scoping insight on antiviral drugs against COVID-19
by: Ahmed S. Ali, et al.
Published: (2021-10-01) -
Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
by: Filippo Albani, et al.
Published: (2020-08-01)